Hematology News

The FDA has granted orphan drug designation to SIG-001, an investigational therapy under evaluation for hemophilia A, according to a press release from the drug’s manufacturer.

Survivors of most types of cancers demonstrated increased medium- to long-term risk for at least one cardiovascular disease compared with the general population, according to results of a retrospective study published in The Lancet.

Researchers at West Virginia University have found that p53-TIGAR-mediated glycolytic suppression decreases DNA damage, improves chromosomal instability and consequently prevents premature exhaustion in Fanconi anemia hematopoietic stem cells.

A noninvasive prenatal test developed by researchers in the United Kingdom appeared effective for diagnosis of sickle cell disease among a small patient sample.

Adjuvant low-dose rituximab in combination with plasma exchange and steroids appeared effective for the treatment of acquired thrombotic thrombocytopenic purpura, according to results of a prospective, single-arm phase 2 study published in Blood.

Venous thromboembolism risk factors appeared highly prevalent among postpartum women at a Dublin hospital, according to results of a cross-sectional study published in Journal of Thrombosis and Haemostasis.

Rivaroxaban and dabigatran reduced the risk for venous thromboembolism in children, according to three studies presented at the International Society on Thrombosis and Haemostasis Congress.

Extended treatment with oral edoxaban appeared comparable to subcutaneous dalteparin in safety and effectiveness for prevention of recurrent venous thromboembolism and major bleeding among patients with active cancer, according to results of a post-hoc analysis published in Journal of Thrombosis and Haemostasis.

Administering 20 mL/kg or 30 mL/kg blood transfusions immediately produced similar clinical outcomes over 6 months among African children with severe anemia compared with a triggered strategy, according to results of two randomized trials published in The New England Journal of Medicine.

Pregnancy appeared associated with increased risk for transfusion reactions among women who received blood products, with preeclampsia as the most significant risk factor for complications, according to study results published in Blood Advances.